Unravelling resistance mechanisms of oncolytic viruses in glioblastoma
Glioblastoma (GBM) is an aggressive primary brain tumor with a major unmet medical need. Oncolytic viruses (OVs) show promise for GBM treatment, but complete remissions remain rare. The intratumoral heterogeneity of GBM drives therapeutic escape and emergence of OV-resistant subclones. Beyond the well-characterized interferon-mediated antiviral response, mechanisms driving OV resistance remain poorly understood. To identify new markers of tumor-intrinsic OV resistance in GBM, we exposed 14 GBM patient-derived cell lines (GBM-PDCLs) to 6 OVs and generated virus-resistant subpopulations from surviving cells. Focusing on Sindbis (SINV)- and H1-parvovirus (H1PV)-resistant cells, we showed that resistance is associated with impaired viral replication. Gene set enrichment analysis of transcriptomic profiles revealed that resistance to both SINV and H1PV correlated with downregulated glutamate receptor signaling. In contrast, collagen fibril organization was downregulated in SINV-resistant GBM PDCLs but upregulated in H1PV-resistant cells. Functional validation confirmed opposing effects of collagen degradation on SINV and H1PV oncolytic activity. One SINV-resistant GBM-PDCL showed cross-resistance to multiple OVs, which was associated with increased expression of antiviral immunity genes and increased dependence on type I interferon signaling for survival. Together, these findings reveal shared and virus-specific cellular processes driving OV resistance in GBM, providing a basis for strategies to overcome resistance.